Anterior Gradient-3: A novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models

► AGR2 is a pro-oncogenic protein implicated in Tamoxifen resistance and metastasis. ► AGR3 is the conserved AGR2 orthologue whose role in cancer is unclear. ► Monoclonal antibodies were generated towards AGR3 to evaluate its expression in vivo. ► AGR3 was expressed in four ovarian cancer subtypes and was uncoupled from AGR2. ► AGR3 mediates cisplatin resistance in vivo and presents a novel drug target.